Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 8/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4013833 | 0.76 | MEN1 (0.58) | MEN1KMT2ACCNE1CDK2CCNE2 | |
| SCHEMBL4014651 | 0.74 | MEN1 (0.51) | MEN1KMT2ACCNE1CDK2CCNE2 | |
| SCHEMBL4014645 | 0.74 | MEN1 (0.51) | MEN1KMT2ACCNE1CDK2CCNE2 | |
| SCHEMBL4015689 | 0.70 | FLT3 (0.49) | MEN1KMT2ACCNE1CDK2CCNE2 | |
| SCHEMBL4019880 | 0.70 | FLT3 (0.49) | MEN1KMT2ACCNE1CDK2CCNE2 | |
| SCHEMBL6392846 | 0.70 | LRRK2 (0.74) | MEN1KMT2ACCNE1CDK2CCNE2 | |
| SCHEMBL6392850 | 0.70 | LRRK2 (0.74) | MEN1KMT2ACCNE1CDK2CCNE2 | |
| SCHEMBL14674721 | 0.70 | KDR (0.66) | MEN1KMT2ACCNE1CDK2CCNE2 | |
| SCHEMBL14674722 | 0.70 | KDR (0.66) | MEN1KMT2ACCNE1CDK2CCNE2 | |
| SCHEMBL1848038 | 0.69 | RET (0.73) | MEN1KMT2ACCNE1CDK2CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009085040-A1 | PROTEIN KINASE INHIBITORS | DCB-USA LLC (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163494-A1 | PROTEIN KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163494-A1 | PROTEIN KINASE INHIBITORS | BRAF, MAP3K20, SELENOI | MEN1 893/4885KMT2A 1340/4885CCNE1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.